[go: up one dir, main page]

AR084226A1 - Derivados de bencimidazol-amidas, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades inflamatorias asociadas con el dolor - Google Patents

Derivados de bencimidazol-amidas, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades inflamatorias asociadas con el dolor

Info

Publication number
AR084226A1
AR084226A1 ARP110104608A ARP110104608A AR084226A1 AR 084226 A1 AR084226 A1 AR 084226A1 AR P110104608 A ARP110104608 A AR P110104608A AR P110104608 A ARP110104608 A AR P110104608A AR 084226 A1 AR084226 A1 AR 084226A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
groups
last
substituents selected
Prior art date
Application number
ARP110104608A
Other languages
English (en)
Inventor
Roland Pfau
Dirk Stenkamp
Henri Doods
Alexander Heim-Riether
Raimund Kuelzer
Klaus Rudolf
Henning Priepke
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR084226A1 publication Critical patent/AR084226A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) en la que R1 representa halo, OH, -CN, alquilo C1-3, alquinilo C2-6, O-alquilo C1-3, estando estos tres últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CN, =O, OH, -OCH3, -OCF3; R2 representa halo, -CN, alquilo C1-3, O-alquilo C1-3, estando estos dos últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CN, =O, OH, -OCH3, -OCF3; R3 y R4 representan independientemente hidrógeno, halo, -CN, alquilo C1-3, O-alquilo C1-3, estando estos dos últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CN, =O, OH, -OCH3, -OCF3; Ra, Rb representan independientemente hidrógeno, alquilo C1-3 opcionalmente sustituido con uno o más átomos de fluoro, o ambos junto con el átomo de carbono al que están unidos, forman un anillo de cicloalquileno C3-7, o un anillo de heterocicloalquileno de 4 - 6 miembros, estando estos dos últimos anillos opcionalmente sustituidos con uno o más átomos de flúor; W representa -C(O)-, -S(O)-, -S(O)2-, -C(O)O-, C(O)NRd- y estos grupos están unidos al nitrógeno del resto -NH- mediante un átomo de carbono o de azufre; Rd representa hidrógeno, alquilo C1-3; M representa alquilo C1-8, alquinilo C2-8, cicloalquil C3-8-alquilo C0-4, (heterocicloalquil de 4 - 10 miembros)-alquil C0-4-, estando estos cuatro últimos grupos opcionalmente sustituidos con uno o más grupos seleccionados de fluoro, -OH, =O, -CN, -NH2, alquilo C1-3, -NH(alquil C1-3), -N(alquil C1-3)2, azetidinilo, pirrolidinilo, piperidinilo, -O-alquilo C1-3 [y estos siete últimos grupos alquilo pueden estar sustituidos con uno o más sustituyentes seleccionados de fluoro, OH, -CN, O-alquilo C1-2 (y este último grupo alquilo está opcionalmente sustituido con uno o más átomos de flúor)], arilo, heteroarilo [estando estos dos últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de halo, OH, -CN, alquilo C1-3, O-alquilo C1-3 (estando estos dos últimos grupos alquilo opcionalmente sustituidos con uno o más átomos de flúor)], o arilo, heteroarilo, estando estos dos últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de halo, -OH, -CN, -NH2, arilo, heteroarilo [estando estos dos últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de halo, OH, -CN, alquilo C1-3, -O-alquilo C1-3 (estando estos dos últimos grupos alquilo opcionalmente sustituidos con uno o más átomos de flúor)], alquilo C1-7, alquinilo C2-7, cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros, -NH(alquil C1-3), -N(alquil C1-3)2, -O-alquilo C1-3, -O-alquil C0-2-arilo, -S-alquilo C1-3, (estando estos últimos grupos alquilo, alquinilo, heterocicloalquilo, arilo o cicloalquilo, opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CN, =O, -NH2, -NH(alquil C1-3), -N(alquil C1-3)2, -OH, -O-alquilo C1-3)]; R6 representa hidrógeno, alquilo C1-5, alquinilo C3-6, (heterocicloalquil de 4 - 7 miembros)-alquilo C0-2 o cicloalquil C3-7-alquilo C0-2 [estando estos cuatro últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CN, =O, -C(O)-NH2, -C(O)-NH(alquil C1-3), -C(O)-N(alquil C1-3)2, alquilo C1-3 opcionalmente sustituido con OH o fluoro, -OH, -NH2, -O-alquilo C1-3, -NH(alquil C1-3), -N(alquil C1-3)2]; R7 y R9 representan independientemente hidrógeno, halo, -CN, alquilo C1-5, cicloalquil C3-5-alquil C0-2-, alquil C1-5-O-, cicloalquil C3-5-alquil C0-2-O- (y en estos cuatro últimos grupos los fragmentos alquilo y cicloalquilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CN, =O, OH, -O-alquilo C1-3 o con uno o más grupos alquilo C1-3 que están opcionalmente sustituidos con uno o más átomos de flúor); L representa -NH2, -NHR10, -NR10R11, o un grupo heterocicloalquilo de 4 - 10 miembros que está unido al bencimidazol a través de un átomo de nitrógeno y que puede estar opcionalmente anillado con un fenilo o con un anillo heteroarilo de 5 ó 6 miembros y que está opcionalmente sustituido con uno o más sustituyentes R12; R10 y R11 representan independientemente alquilo C1-7, alquinilo C3-6, cicloalquil C3-7-alquil C0-4- o heterocicloalquil C4-7-alquil C0-4- [estando estos cuatro últimos grupos opcionalmente sustituidos con uno o más grupos seleccionados de fluoro, -OH, NH2, -C(O)NH2, -CN, =O, alquilo C1-3, -NH(alquil C1-3), -N(alquil C1-3)2, -O-alquilo C1-5, -O-cicloalquilo C3-6, -O-heterocicloalquilo C4-6, -S-alquilo C1-3, -S(O)alquilo C1-3, -S(O)2-alquilo C1-3 (estando estos nueve últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CF3, -CHF2, -CH2F, -CH3)], o aril-alquil C0-4, heteroaril-alquil C0-4- [estando estos dos últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de halo, -OH, -NH2, -CN, alquilo C1-3, cicloalquilo C3-5, alquil C1-3-O-, cicloalquil C3-5-O- (estando estos cuatro últimos grupos opcionalmente sustituidos con uno o más átomos de flúor)]; cada R12 representa independientemente halo, -OH, -NH2, =O, -CN, -C(=O)-NH2, alquilo C1-4, cicloalquil C3-5-alquil C0-2-, heterocicloalquil C4-5-alquil C0-2-, alquil C1-4-O-, alquil C1-3-C(=O)-, -C(O)-NH(alquil C1-3), -C(=O)-N(alquil C1-3)2 [estando estos siete últimos grupos opcionalmente sustituidos con uno ó más grupos seleccionados de: fluoro, -OH, oxo, -NH2, -CN, alquilo C1-3, -NH(alquil C1-3), -N(alquil C1-3)2, -O-alquilo C1-3, -O-cicloalquilo C3-5 (estando estos cinco últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CF3, -CHF2, -CH2F)], o aril-alquil C0-4-, heteroaril-alquil C0-4- [estando estos dos últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de halo, -OH, -CN, alquilo C1-3, cicloalquilo C3-5, alquil C1-3-O-, cicloalquil C3-5-O- (estando estos cuatro últimos grupos opcionalmente sustituidos con uno o más átomos de flúor)]; A representa alquilo C1-8, alquinilo C3-8, aril-alquil C0-3-, cicloalquil C3-8-alquil C0-3, (heterocicloalquil de 4 - 7 miembros)-alquil C0-3-, heteroaril-alquil C0-3, y en estos seis últimos grupos los fragmentos alquil-, alquinil-, cicloalquil- y heterocicloalquil- están opcionalmente sustituidos con uno o más sustituyentes seleccionados de R14 y los fragmentos arilo y heteroarilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados de R15; cada R14 representa independientemente fluoro, -OH, -CN, =O, -NH2, -NH(alquil C1-3), -N(alquil C1-3)2, -O-alquilo C1-6, alquilo C1-6 [y en estos cuatro últimos grupos los fragmentos alquilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CN, =O, -NH2, -NH(alquil C1-3), N(alquil C1-3)2, -OH, -O-alquilo C1-3] o arilo, heteroarilo [estando estos dos últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de halo, OH, -CN, alquilo C1-3, O-alquilo C1-3 (estando estos dos últimos grupos alquilo opcionalmente sustituidos con uno o más átomos de flúor)]; cada R15 representa independientemente halo, -OH, -CN, -NH2, -NH(alquil C1-3), -N(alquil C1-3)2, -O-alquilo C1-3 [y en estos tres últimos grupos los fragmentos alquilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CN, =O, -NH2, -NH(alquil C1-3), N(alquil C1-3)2, -OH, -O-alquilo C1-3] o arilo, heteroarilo [estando estos dos últimos grupos opcionalmente sustituidos con uno o más sustituyentes seleccionados de halo, OH, -CN, alquilo C1-3, O-alquilo C1-3 (estando estos dos últimos grupos alquilo opcionalmente sustituidos con uno o más átomos de flúor)] o alquilo C1-7, alquinilo C2-7, cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros [estando estos últimos grupos alquilo, alquinilo, heterocicloalquilo o cicloalquilo opcionalmente sustituidos con uno o más sustituyentes seleccionados de fluoro, -CN, =O, -NH2, -NH(alquil C1-3), N(alquil C1-3)2, -OH, O-alquilo C1-3]; o una de sus sales, particularmente una de sus sales fisiológicamente aceptables.
ARP110104608A 2010-12-10 2011-12-12 Derivados de bencimidazol-amidas, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades inflamatorias asociadas con el dolor AR084226A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10194458 2010-12-10

Publications (1)

Publication Number Publication Date
AR084226A1 true AR084226A1 (es) 2013-05-02

Family

ID=43726122

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104608A AR084226A1 (es) 2010-12-10 2011-12-12 Derivados de bencimidazol-amidas, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades inflamatorias asociadas con el dolor

Country Status (17)

Country Link
US (1) US8674113B2 (es)
EP (1) EP2649051A1 (es)
JP (1) JP5808820B2 (es)
KR (1) KR20130143076A (es)
CN (1) CN103402987A (es)
AR (1) AR084226A1 (es)
AU (1) AU2011340482A1 (es)
BR (1) BR112013014314A2 (es)
CA (1) CA2820838A1 (es)
CL (1) CL2013001654A1 (es)
EA (1) EA201300684A1 (es)
IL (1) IL226328A0 (es)
MX (1) MX2013006083A (es)
NZ (1) NZ610312A (es)
PH (1) PH12013501175A1 (es)
UY (1) UY33779A (es)
WO (1) WO2012076673A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
CN103601675B (zh) * 2013-10-08 2015-10-28 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
UY38806A (es) * 2019-08-01 2021-02-26 Novartis Ag Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos
ES2973832T3 (es) 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
AU2020374947C1 (en) 2019-10-31 2025-05-08 Forty Seven, LLC Anti-CD47 and anti-CD20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
JP7564888B2 (ja) 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
JP2024546851A (ja) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CA3249472A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. KIRSTEN G12D RAT SARCOMA VIRUS MODULATOR COMPOUNDS
AU2023298558A1 (en) 2022-07-01 2024-12-19 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3006671A1 (de) 1980-02-22 1981-08-27 Dr. Karl Thomae Gmbh, 7950 Biberach Neue benzoxazole, deren herstellung und deren verwendung als arzneumittel
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
ES2276530T3 (es) 1998-08-26 2007-06-16 Aventis Pharma Limited Azabiciclos qu4e modelan la inhibicion de la adherencia celular.
DE60027700T2 (de) 1999-02-16 2007-05-03 Aventis Pharma Ltd., West Malling Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
AU769554B2 (en) 1999-04-12 2004-01-29 Aventis Pharma Limited Substituted bicyclic heteroaryl compounds as integrin antagonists
DE60041487D1 (de) 1999-05-05 2009-03-19 Aventis Pharma Ltd Substituierte bizyclische verbindungen
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
MXPA02003364A (es) 1999-10-06 2002-08-23 Boehringer Ingelheim Pharma Compuestos heterociclicos utiles como inhibidores de las cinasas de tirosina.
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
EP1487824B1 (en) 2002-03-01 2007-06-20 SmithKline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
EA007987B1 (ru) 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
JP4768265B2 (ja) 2002-10-15 2011-09-07 シンタ ファーマシューティカルズ コーポレーション 新規化合物
EP1603905A1 (en) 2003-02-10 2005-12-14 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
US7329682B2 (en) 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
CA2543707A1 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
KR20070029809A (ko) 2004-06-18 2007-03-14 바이올리폭스 에이비 염증치료에 유용한 인돌
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
EP1841735B1 (en) 2005-01-19 2011-03-09 Biolipox AB Indoles useful in the treatment of inflammation
US20100130473A1 (en) 2005-02-25 2010-05-27 Marc Geoffrey Hummersone Compounds
EP2295432A1 (en) 2006-02-10 2011-03-16 TransTech Pharma Inc. Process for the preparation of aminobenzimidazole derivatives
WO2008009924A2 (en) 2006-07-18 2008-01-24 Biolipox Ab Indoles useful in the treatment of inflammation
WO2008035956A1 (en) 2006-09-22 2008-03-27 Ewha University - Industry Collaboration Foundation New benzoxazole derivative, process for the preparation thereof and pharmaceutical composition comprising the same
JP2010513253A (ja) 2006-12-14 2010-04-30 ベーリンガー インゲルハイム インテルナショナール ゲーエムベーハー 炎症の治療に有用なベンゾオキサゾール類
WO2008129276A1 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds

Also Published As

Publication number Publication date
IL226328A0 (en) 2013-07-31
JP2014502281A (ja) 2014-01-30
CN103402987A (zh) 2013-11-20
EP2649051A1 (en) 2013-10-16
NZ610312A (en) 2015-11-27
UY33779A (es) 2012-07-31
CL2013001654A1 (es) 2014-03-28
US8674113B2 (en) 2014-03-18
CA2820838A1 (en) 2012-06-14
US20120149676A1 (en) 2012-06-14
JP5808820B2 (ja) 2015-11-10
KR20130143076A (ko) 2013-12-30
EA201300684A1 (ru) 2013-12-30
WO2012076673A1 (en) 2012-06-14
BR112013014314A2 (pt) 2016-09-27
PH12013501175A1 (en) 2017-08-23
AU2011340482A1 (en) 2013-05-30
MX2013006083A (es) 2013-07-02

Similar Documents

Publication Publication Date Title
AR084226A1 (es) Derivados de bencimidazol-amidas, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades inflamatorias asociadas con el dolor
AR075789A1 (es) Derivados de bencimidazol, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de la prostaglandina microsomica e2 sintasa-1 (mpnges-1)
AR081315A1 (es) Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
AR075731A1 (es) Derivados heterociclicos de bencimidazoles, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento del virus sincicial respiratorio(vsr).
AR082102A1 (es) Derivados de acido (2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos
AR082112A1 (es) Derivados de imidazopiridina, su procedimiento de preparacion y su aplicacion en terapeutica
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR063906A1 (es) Compuestos quimicos derivados del indazol, una composicion farmaceutica y procesos de prpeparacion de los compuestos
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR067759A1 (es) Compuestos de pirazol utiles como moduladores de la enzima raf asociada al crecimiento celular anormal
PE20150400A1 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
CU20080165A7 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
AR082103A1 (es) Derivados de dioxido de 1,3-propano sustituidos de manera espirociclica, composiciones farmaceuticas que los contienen y su uso como agentes antidiabeticos
AR098014A1 (es) Compuestos de quinolina selectivamente sustituida
AR082726A1 (es) Derivados de triazolopirazina
AR065372A1 (es) Derivados de purina
MX358651B (es) Nuevos sulfoxidos de piperidino-dihidrotienopirimidina y su uso para tratar enfermedad pulmonar obstructiva cronica (epoc) y asma.
AR082768A1 (es) Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
ECSP13012771A (es) Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos
MX2018008131A (es) Forma cristalina del inhibidor de la btk quinasa y metodo de preparacion de la misma.
CU20090048A7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR082727A1 (es) Derivados de furopiridina, procesos de preparacion y composiciones farmaceuticas que los contienen
CO6351734A2 (es) Compuestos de amida utiles en terapia
AR086590A1 (es) Compuestos de ciclohexanona y herbicidas que los comprenden

Legal Events

Date Code Title Description
FB Suspension of granting procedure